Diadenosine polyphosphates in the tears of aniridia patients by Peral Cerdá, Assumpta et al.
Diadenosine polyphosphates in the tears of aniridia
patients
Assumpta Peral,1 Gonzalo Carracedo1 and Jesus Pintor2
1Department of Optics II (Optometry & Vision), Faculty of Optics and Optometry, University Complutense of Madrid, Madrid,
Spain
2Department of Biochemistry and Molecular Biology IV, Faculty of Optics and Optometry, University Complutense of Madrid,
Madrid, Spain
ABSTRACT.
Purpose: To quantify diadenosine polyphosphate levels in tears of congenital
aniridia patients to estimate the ocular surface changes associated with
congenital aniridia compared to normal individuals.
Methods: Fifteen patients diagnosed with congenital aniridia and a control
group of forty volunteers were studied. Tears were collected to quantify the levels
of diadenosine polyphosphates Ap4A and Ap5A by high-performance liquid
chromatography (H.P.L.C). Break-up time (BUT), corneal staining, McMon-
nies questionnaire and the Schirmer I test were applied to both groups.
Results: Dinucleotides in congenital aniridia patients were higher than in control
subjects. For the congenital aniridia group, under 15 years old, the values were
0.77  0.01 lM and 0.17  0.02 lM for Ap4A and Ap5A, respectively. The
group aged from 15 to 40 years old provided concentrations of 4.37  0.97 lM
and 0.46  0.05 lM for Ap4A and Ap5A, the group over 40 gave concentrations
of 11.17  5.53 lM and 0.68  0.17 lM for Ap4A and Ap5A. Dinucleotide
concentrations increased with age, being statistically signiﬁcant diﬀerent among
the three age groups (p < 0.05). Congenital aniridia patients showed a normal
tear secretion and no dry eye McMonnies scores, except for the group over
40 years old. BUT values decreased and corneal staining increased with age and
correlated with the levels of diadenosine polyphosphates (p < 0.05).
Conclusions: The levels of dinucleotides in tears increase in aniridia patients
compared with healthy subjects, and they seem to be related with the progression
of corneal disorders in aniridia patients, both of which increase with ageing.
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Introduction
Aniridia is a rare congenital disorder
with a variety of alterations in diﬀerent
organs, including problems in the
development of the eye. It is due to
the mutation of the PAX6 gene (Ton
et al. 1991; Glaser et al. 1992), located
in the short arm of the chromosome 11.
This pathology aﬀects between
1:72 000 and 1:100 000 live births and
presents a wide spectrum of associated
ocular and non-ocular disorders
(Nelson et al. 1984; Eden et al. 2008).
The main feature of aniridia is the
partial or total absence of the iris, but
this aﬄiction is also associated with
other ocular anomalies such as cata-
racts, glaucoma, nystagmus, foveal
hypoplasia, limbal stem cell deﬁciency,
tear ﬁlm disorders and keratopathy
(Mayer et al. 2003). Moreover, aniridia
may be found alone or in association
with other syndromes (Nelson et al.
1984), the latter involving systemic
implications, due to the deletion of
11p13 involving both PAX6 and WT1
genes and known as WARG syndrome
(Fantes et al. 1992).
Although aniridia is a congenital
condition, the severity of most of the
associated ocular pathologies increases
with age. Interestingly, one of the most
relevant pathological situations related
to aniridia is keratopathy. This is
produced by a stem cell deﬁciency,
which furthermore leads to corneal
opacity and to dry eye conditions
(Tseng & Li 1996).
Aniridia-related corneal dystrophy,
termed as aniridic keratopathy, was
originally described by Mackman et al.
(1979), who found a prevalence of
89%, conﬁrmed by other studies
(Kremer et al. 1993; Nishida et al.,
1995). During the progress of the
aniridic keratopathy, the epithelium
becomes thickened and irregular
(Whitson et al. 2005). Later, a periph-
eral pannus appears advancing towards
the central cornea, and the corneal
surface is replaced by conjunctiva-like
epithelium (Gomes et al. 1996). All
these events generate, in addition to
an important visual loss, an irregular
ocular surface where the tear ﬁlm
evaporation rate is high, giving rise to
a potential dry eye disease.
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Analytical techniques provide valu-
able information about novel compo-
nents in tears that may have important
biochemical and physiological func-
tions. Among these new tear compo-
nents, the diadenosine polyphosphates
emerge as interesting compounds due
to their intracellular and extracellular
physiological actions (Miras-Portugal
et al. 1999; McLennan 2000).
Although the activity of these dinucle-
otides in ocular tissues is a matter of
current research, it is already known
that they modulate intraocular pres-
sure in rabbits (Pintor et al. 2003),
Ap4A improves the rate of wound
healing in the cornea of New Zealand
white rabbits, in contrast to Ap5A
inhibits it (Pintor et al. 2004; Mediero
et al. 2006), and Ap4A can stimulate
tear secretion after a single-dose topical
application in rabbits (Pintor et al.
2002a,b). The description of the pres-
ence of diadenosine polyphosphates in
human tears in 2002 (Pintor et al.
2002a,b) and the subsequent report of
these substances as potential molecular
markers for dry eye in 2006 (Peral et al.
2006; Carracedo et al. 2010) suggested
to us the possibility of a relationship
between the amounts of these sub-
stances and the development of dry
eye. Besides this assertion, it has also
been suggested that the shear stress
over the ocular surface, due to the
blink process, is one of the stimuli for
release of these nucleotides into the
tear ﬁlm (Carracedo et al. 2013).
Therefore, in the present experimental
work, the level of diadenosine polyph-
osphates in the tears of a group of
aniridia patients was examined. It is of
interest to relate the changes in con-
centrations of these compounds with
the progress of this disease, relating it
to the changes in the ocular surface as
it progresses with ageing.
Methods
Subjects
The study was conducted in compli-
ance with good clinical practice guide-
lines, institutional review board
regulations and the tenets of the Dec-
laration of Helsinki. The subjects
signed an informed consent and were
free to interrupt the session at any time.
Fifteen aniridia patients (24 eyes) of
both sexes, ﬁve females and 10 males,
enrolled in the Spanish Association of
Aniridia, participated voluntarily in the
study. The ages of the participants
ranged from 8 to 52 years old with an
average age of 25.5  15.6. The sample
was divided into three groups of age:
under 15 years old (n = 7; one female,
six males), between 15 and 40 (n = 4;
two females, two males) and over
40 years of age (n = 4; two females,
two males).
A control group of 40 volunteers
with neither aniridia nor evidence of
symptoms or clinical dry eye disease
participated in the present study. Con-
trols average age of 29.0  1.3 years
were divided into the same age groups
as the aniridia sample: under 15 years
old (n = 11; three females, eight males),
between 15 and 40 (n = 19; 10 females,
nine males) and over 40 years of age
(n = 10; four females, six males).
Trials
To know the dry eye symptomatology
associated to the aniridia patients, the
McMonnies test was performed. This is
a 12-items test used as a screening tool
in the dry eye clinic population. The
dry eye diagnosis is based on the score
obtained with the questionnaire
(McMonnies et al. 1998). A score
below 10 indicates a normal individual
and between 10 and 20 is considered a
marginal dry eye patient and a score
above 20, a dry eye patient.
The tear collection was always per-
formed after ﬁlling in the question-
naire. The volume of tears was
collected using the Schirmer I test
(Jones test). The Schirmer strip was
located on the temporal tarsal conjunc-
tiva of the lower lid for 5 minutes with
the eyes closed. The volume of tears, as
millimetres of moistened strip, was
recorded and the wet part of strips
were placed in Eppendorf tubes con-
taining 500 ll of Ultrapure water and
then the samples were frozen until
processed for the high-pressure liquid
chromatography (H.P.L.C) analysis.
After Schirmer I test, ﬂuorescein was
applied to evaluate break-up time
(BUT) and corneal staining. To war-
rant repeatability of the staining
procedure, a solution was prepared
using a 10% concentration of sodium
ﬂuorescein diluted in saline (NaCl
0.9%). For each application, a micro-
pipette with 5 ll of diluted ﬂuorescein
solution was applied to the inferior
conjunctival sac, and 20 seconds later,
BUT was analysed using a chrono-
graph to record the time to break the
tear after the patient was asked to blink
twice and maintain their eyes open.
The cornea was divided into ﬁve areas
to record the grading staining as
proposed in the report of the National
Eye Institute and Industry-Sponsored
Dry Eye Workshop (2007), and the
Cornea andContactLensResearchUnit
(CCLRU) grading scales were used.
Tear processing and H.P.L.C. analysis
The Schirmer strips collected and
placed in the Eppendorf tubes were
then strongly vortexed for 5 min. The
strips were carefully rinsed, and the
liquid in the tube was heated in a 98°C
dry bath for 2 min to precipitate pro-
teins. To pellet the proteins, tubes were
submitted to centrifugation at 152 g for
30 min. Diadenosine polyphosphates
are resistant to this treatment as dem-
onstrated elsewhere (Pintor et al.
1991). Supernatants were chromato-
graphed through SEP-PAK Accell
QMA cartridges (Pintor et al. 1992).
Brieﬂy, 250 ll of the supernatants were
passed through the cartridges which
were previously equilibrated with 3 ml
of ultrapure water. The elution of the
nucleotides and dinucleotides was per-
formed by applying 1 ml of a solution
containing 0.2 M KCl and 0.1 M HCl.
Prior to the injection in the H.P.L.C,
samples were neutralized with KOH.
These eluents were injected at a volume
of 10–100 ll into the H.P.L.C for their
analysis. Determination and quantiﬁ-
cation of diadenosine polyphosphates
were performed by H.P.L.C, described
by Pintor et al. (Pintor et al. 1992).
Statistical analysis
The presented data were analysed using
the statistical software SPSS 15.0 (SPSS,
Inc., Chicago, IL, USA). The values
presented are the means  SEM of the
experiments performed. Normal distri-
bution of variables was assessed by the
Kolmogorov–Smirnov normality test.
Sample size calculations were
performed with statistical software
(Granmo 6.0; Institut Municipal d’In-
vestigacion Medica, Barcelona, Spain).
With an accepted two-sided statistical
signiﬁcance threshold of 0.05 and a risk
of 0.20 and taking into account a 2:1
group ratio (control group to Congen-
ital Aniridia group), at least 16 subjects
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were needed in the ﬁrst group and 8 in
the second, to ﬁnd statistically signiﬁ-
cant diﬀerences.
Diﬀerences between the congenital
aniridia and control group were esti-
mated by the Student’s t-test for
independent samples between total
groups. As sample sizes of aged groups
were small, Mann–Whitney U-tests
were used to compare values between
the congenital aniridia and control
aged groups. To correlate Schirmer
values with nucleotides concentrations
and McMonnies values, Pearson bivar-
iate regression was used. p < 0.05 was
considered statistically signiﬁcant.
Results
All patients over 40 years old and one
patient between 15 and 40 years of age
were treated with amniotic membrane
12 months before the study. None of
the patients of aniridia group had
undergone limbal graft or any other
corneal surgery prior to the study.
Three of them (one of them belonged
to 15–40 year old subgroup and two
belonged to over 40 years old) were
waiting for limbal graft surgery, and
they were due to undergo surgery in the
following 6 months after the study.
The distribution of subjects and the
parameters evaluated for the diﬀerent
groups are summarized in Table 1.
Related to the volume of tears, it was
considered a normal Schirmer test I
above 5 mm of moistened strip (van
Bijsterveld 1969).
As mentioned in materials and
methods, both groups were divided
into three diﬀerent age groups. The
scores of the McMonnies questionnaire
revealed diﬀerent values for each sub-
group, as can be seen in Table 1. Just
one subgroup in aniridia group and the
same subgroup in control group that
corresponding to over 40 years old
showed a borderline dry eye score
(McMonnies et al. 1998), while the
others were not considered dry eye
patients. The ANOVA test for the
McMonnies scores did not show sig-
niﬁcant diﬀerences in any of the groups
(p = 0.033).
Each subgroup of aniridia patients
presented diﬀerent percentages of inci-
dence for the symptoms studied in the
questionnaire. The group under
15 years of age, presented dryness and
grittiness in 28%, meanwhile soreness,
burning and scratchiness had a per-
centage of 14%. The second group,
from 15 to 40, showed soreness, dry-
ness and scratchiness with a percentage
of 50% and grittiness and burning in
25%. The group over 40 years old
presented all the symptoms with a
percentage ranging from 25 to 75%.
This group showed the highest
percentage of incidence for the dryness
symptom.
The volumes of tear secretion, BUT
and corneal staining of the aniridia
patients and control group are listed in
Table 1. These results show normal
tear secretion values for all the age
groups, and there were no signiﬁcant
diﬀerences among the groups. Con-
cerning the tear break-up time (BUT),
we have found a decrease in the con-
genital aniridia group compared to the
control group, (p < 0.05). On the other
hand, we had statistically signiﬁcant
diﬀerences in the corneal staining,
where the score was a third higher in
the aniridia group than in controls
(p < 0.05). Also, statistically signiﬁcant
diﬀerences were found between con-
trols and aniridia patients in all age
groups (p < 0.05).
H.P.L.C. analysis
The results obtained from the chro-
matographic proﬁles showed a gradual
increase in the concentration of the
substances with age, as can be seen in
Fig. 1. The highest values, correspond-
ing to the group of patients over
40 years of age, were the values for
Ap4A and Ap5A, which were 11.18
 5.53 lM and 0.68  0.17 lM, respec-
tively, as can be seen in Table 1. The
variations among the diﬀerent groups
of age were statistically signiﬁcant
Table 1. Summary of parameters evaluated for control and aniridia groups.
Group Control Aniridia p-Value
Age
Mean  SEM
Total 29.02  1.30 25.25  3.35 0.208
Schirmer (mm)
Mean  SEM
Total 19.93  1.26 18.89  1.96 0.664
BUT (seconds)
Mean  SEM
Total 16.34  1.04 8.85  2.55 0.002*
Corneal staining
Mean  SEM
Total 1.34  0.15 3.18  0.16 <0.001*
McMonnies
Mean  SEM
Total 8.30  0.86 6.86  1.52 0.396
Ap4A (lM)
Mean  SEM
Total 0.15  0.02 5.28  0.77 <0.001*
Ap5A (lM)
Mean  SEM
Total 0.91  0.02 0.45  0.03 <0.001*
*p-Value < 0.05 (Student’s t-test independent samples; control vs. aniridia groups).
2 4 6 80
0.002
AUFS
10 12 14 16 18 20
Retention time (min)
Control
15<
15-40
40>
0.01
AUFS
Standard
Ap4A
Ap5A
Fig. 1. Diadenosine polyphosphate detection
in tears of aniridia patients. Chromatographic
analysis of samples from aniridia patients
showing the presence of two peaks identiﬁed
as Ap4A and Ap5A when compared to a
commercial standard (upper record). A control
record (representing a healthy individual) can
be compared with representative traces of
aniridia patients grouped, according to meth-
ods, in three groups of age. Note that stan-
dards scale bar is diﬀerent from the one for the
samples. AUFS, absorbance units full scale.
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(p = 0.038, ANOVA for Ap4A and
p = 0.003, ANOVA) for Ap5A. Statisti-
cally signiﬁcant diﬀerences were found
among all the groups of aniridia
patients and their control groups
(p < 0.01, Wilcoxon Mann–Whitney
U-test) as well as for the mean total
group (p < 0.01, Student’s t-test).
Comparing the values of Ap4A and
Ap5A in the aniridia patients with their
respective control age groups, these
substances were several folds higher.
Thereby, levels of Ap4A and Ap5A
were 36 and 3.8 times more concen-
trated in aniridia patients for the group
between 15 and 40 years old, respec-
tively, and 86 and 17 times more for the
group over 40 as is shown in Figs 2
and 3.
The Pearson’s correlation coeﬃ-
cients for Schirmer, BUT and corneal
staining scores and Ap4A were 0.580
(p = 0.003), 0.235 (p = 0.137) and
0.692 (p = 0.001), respectively. The
value of these coeﬃcients indicate a
moderate degree of correlation Ap4A
with Schirmer test and corneal staining
but not with BUT.
Discussion
The present experimental work shows
that patients with aniridia have ele-
vated concentrations of diadenosine
polyphosphates, Ap4A and Ap5A, in
their tears when compared to normal
individuals. There is another study
regarding a molecular analysis of the
tear components in congenital aniridia
(Ihnatko et al. 2013). These authors
performed a proteomic tear analysis in
aniridia patients revealing an elevated
expression of bacteriostatic lactoferrin
and a greatly elevated expression of
VEGF in aniridia tears. Both ﬁndings
are related to keratopathy and aniridia
pathophysiology. It seems clear that
further studies are needed to clarify the
involvement of tear molecules in anir-
idia pathophysiology and their poten-
tial as targets of this severe ocular
condition.
When we compared both dinucleo-
tides, Ap4A was always more concen-
trated than Ap5A, which also happens
in healthy individuals. Ap4A and Ap5A
values in the aniridia patients who are
over 40 years of age were higher than
those found in younger aniridia
patients. These results show a gradual
increase of diadenosine polyphosphates
levels with age, which could be linked
to the development of the ocular sur-
face disorders present in the aniridia
patients.
The results obtained in the McMon-
nies tests indicate that, in general, the
scores were not signiﬁcantly diﬀerent
from normal individuals. Only the age
group over 40 years old presented mar-
ginal dry eye. In the search for which
symptoms were markedly diﬀerent
among the diﬀerent groups, dryness
was the one that presented the highest
percentage of incidence, and it was the
one that best correlatedwith the levels of
dinucleotide. Moreover, when we com-
pared the concentrations of the dinucle-
otides in the three age groups with
dryness, the behaviour was similar.
Regarding the tear volume measured
by the Schirmer test, it showed normal
values of secretion in almost all the
groups tested. While the age group
between 15 and 40 presented an appar-
ent lower value of secretion, there were
no signiﬁcant diﬀerences among the
tested groups. As in other studies, there
was no correlation between the symp-
toms and the volume of tear secretion
(Bjerrum 1996; Schein et al. 1997;
Hay et al. 1998). Regarding the tear
secretion values, there is no evidence of
an aqueodeﬁciency in the congenital
aniridia patients, so we would
expect normal levels of diadenosine
Fig. 2. Bar graph representing the concentration of diadenosine polyphosphate Ap4A, expressed
in lM, in tears of control subjects and aniridia patients for any group of age. After the
chromatographic analysis of tear samples, dinucleotide concentrations were calculated by
comparing the peaks in samples to the ones obtained in commercial standards of known
concentrations (see Methods). The values represent the mean  SEM. *p-Value < 0.01 (Student’s
t-test). **p-Value < 0.01 (Wilcoxon Mann–Whitney U-test).
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Figure 3. Bar graph representing the concentration of diadenosine polyphosphate Ap5A,
expressed in lM, in tears of control subjects and aniridia patients for any group of age. After
the chromatographic analysis of tear samples, dinucleotide concentrations were calculated by
comparing the peaks in samples to the ones obtained in commercial standards of known
concentrations (see methods). The values represent the mean  SEM. *p-Value < 0.01 (Student’s
t-test). **p-Value < 0.01 (Wilcoxon Mann–Whitney U-test).
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polyphosphates (Pintor et al. 2002a,b;
Peral et al. 2006), instead of the
increased levels found in the present
work. It is therefore reasonable to
assume that there is at least one other
factor in these patients that increases
the levels of the diadenosine polyphos-
phates in their tears.
In 2004, Pintor et al. described, for
the ﬁrst time, the eﬀect produced by the
topical application of the diadenosine
polyphosphate Ap4A in the corneal
wound healing of New Zealand white
rabbits. This application increased the
rate of corneal wound healing, enhanc-
ing epithelial integrity. In the men-
tioned study, Ap5A did not aﬀect the
rate of re-epithelialization. In Vitro
studies demonstrated that Ap4A
possesses the ability to accelerate cel-
lular migration activating the MAPK
cascade as well as the RhoA/ROK-I
cascade, both of which are necessary
for the cellular migration process. In
contrast, Ap5A would do the opposite
(Mediero et al. 2006, 2008; Crooke
et al. 2009).
The eﬀect that diadenosine polyph-
osphates might present on corneal
erosions and the fact that the patients
with congenital aniridia suﬀer recur-
rent corneal erosions that increase in
severity with age, suggest that the
concentration of Ap4A and Ap5A
found in the tears of aniridia patients
is due to the progression of the limbal
deﬁciency and the corneal epithelial
fragility they present, more than to the
dry eye these patients can suﬀer. Our
results regarding BUT and corneal
staining are the same as in other studies
(Gomes et al. 1996; Jastaneiah &
Al-Rajhi 2005).
Aniridia-associated keratopathy is
caused by limbal stem cell deﬁciency,
among other factors (Lee et al. 2008).
It has been demonstrated that P2
purinergic receptors are associated with
diﬀerentiation, proliferation and neu-
rogenesis in neonatal and adult mouse
olfactory epithelium (Jia et al. 2009; Jia
& Hegg 2010). If something similar
happens in the human eye, it could be
the case that the increased levels of
diadenosine polyphosphates act as a
compensatory mechanism to stimulate
the proliferation and diﬀerentiation of
limbal stem cells which are deﬁcient in
aniridia disorder. This interesting pos-
sibility needs to be investigated in
depth and will, indeed, be the matter
of future studies.
A limiting factor of the present study
was the small size of aniridia aged
groups due to the condition of this rare
disease. Nevertheless, the objective to
divide the aniridia group in aged sub-
groups was not to get a ﬁnal conclusion
but to know the corneal keratopathy
and dinucleotides progression with
ageing. Although it was very diﬃcult
to grade the slit-lamp ﬁndings of the
ocular surface in the whole sample, due
to the discomfort the patients suﬀered,
it is clear that the aniridia patients over
40 years of age showed more corneal
staining than the other groups. Further
investigation needs to be performed to
correlate the concentration of the stud-
ied dinucleotides and the alteration of
the others ocular surface disorders
indicators as an osmolarity or mucin
secretion in aniridia patients.
In conclusion, these stable mole-
cules, Ap4A and Ap5A, increase in
tears of aniridia patients compared
with healthy subjects and are related
with age and aniridia pathophysiology.
Further studies are needed for an
evaluation of this ﬁnding and useful-
ness of this potential biomarker in the
development of new therapies related
to symptomatology in aniridia
patients.
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